Regeneron Pharmaceuticals (REGN) EBITDA (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly EBITDA of $1.3 billion for Q2 2026, up 19.82% year-over-year from $1.1 billion in Q2 2025, and up 101.2% quarter-over-quarter from $642.9 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) EBITDA (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at $1.3 billion for Q2 2026.
- In Q2 2026, EBITDA rose 19.82% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $3.8 billion (changed 0.06% YoY), while the FY2025 annual figure was $3.6 billion, down 10.34% from the prior year.
- EBITDA for Q2 2026 stood at $1.3 billion, up from $642.9 million in the prior quarter.
- The five-year high for EBITDA was $1.3 billion in Q2 2026, with the low at $591.7 million in Q1 2025.
- The 5-year median for EBITDA is $1.0 billion (2024), against an average of $1.0 billion.
- The sharpest annual moves came in 2022 and 2026: EBITDA tumbled 66.84% in 2022, then gained 19.82% in 2026.
- Regeneron Pharmaceuticals' EBITDA stood at $1.1 billion in 2022, then slipped by 15.16% to $972.9 million in 2023, then advanced by 1.78% to $990.2 million in 2024, then decreased by 11.14% to $879.9 million in 2025, then jumped by 47.01% to $1.3 billion in 2026.
- Business Quant data shows REGN's EBITDA at $1.3 billion in Q2 2026, $642.9 million in Q1 2026, and $879.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | 642.90 Mn |
| Dec 31, 2025 | 879.90 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 591.70 Mn |
| Dec 31, 2024 | 990.20 Mn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 1.07 Bn |
| Mar 31, 2024 | 751.40 Mn |
| Dec 31, 2023 | 972.90 Mn |
| Sep 30, 2023 | 1.11 Bn |
| Jun 30, 2023 | 1.02 Bn |
| Mar 31, 2023 | 946.70 Mn |
| Dec 31, 2022 | 1.15 Bn |
| Sep 30, 2022 | 1.22 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.26 Bn |
| Dec 31, 2021 | 2.64 Bn |
| Sep 30, 2021 | 1.85 Bn |